Barr Launches Generic Metaglip Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg
WOODCLIFF LAKE, N.J., January 19, 2007 -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. , today announced that it has launched a generic version of Bristol-Myers Squibb Company's Metaglip (Glipizide and Metformin HCl) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg. The Company is launching a product that is supplied by Teva Pharmaceuticals Industries Ltd. The Company's Abbreviated New Drug Application (ANDA) that was acquired from Ivax Corporation in connection with the acquisition of Ivax by Teva in January 2006 is still pending at the U.S. Food and Drug Administration.
Metaglip (glipizide and metformin HCl) Tablets is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone. Metaglip is indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes.
Barr's Glipizide and Metformin HCl Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg, will compete in a market that had total annual sales of approximately $30 million for the twelve months ending November 2006, according to IMS sales data.
Source: Barr Pharmaceuticals, Inc.
Posted: January 2007